Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neurotrophic receptor tyrosine kinases NTRK1, NTRK2, and NTRK3 encode the transmembrane receptor tyrosine kinases TRKA, TRKB, and TRKC, respectively. These receptors are high-affinity binding sites for neurotrophins and play essential roles in neural development, survival, and function. Aberrant activation, particularly through gene fusions, drives oncogenesis in diverse cancers, making them key targets for precision oncology with TRK inhibitors. Loss-of-function mutations are implicated in neurological disorders.
Selective inhibition of TRK kinase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurotrophic receptor tyrosine kinases (NTRK).